Press

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

Mar 13 • 2 min read

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has applied and received approval for a voluntary delisting of its common shares…

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Mar 13 • 3 min read

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss…

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Mar 12 • 5 min read

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group“) (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ:PBM) (“PBM” or “Psyence Biomed“) has received full approval from the Australian…

atai Life Sciences Advances VLS-01 for Treatment-Resistant Depression

Mar 12 • 2 min read

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Dr Srinivas Rao discusses the company’s development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive’s Stephen Gunnion. Rao explained that VLS-01 is a formulation of DMT, the active component in ayahuasca, known for its short-duration psychedelic effects. The innovation lies in its delivery method, an oral transmucosal…

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Mar 11 • 12 min read

TORONTO, March 11, 2024 (GLOBE NEWSWIRE) — Further to the announcement by Psyence Group Inc (“Psyence Group” or the “Company“) (CSE:PSYG) of the closing (the “Closing”) of the business combination of its subsidiary, Psyence Biomedical Ltd (“PBM“) (NASDAQ:PBM) with Newcourt Acquisition Corp (“Newcourt“), a special purpose acquisition company, (the “Business Combination” or “Spin–Out“) and the subsequent…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436